Epidemic prevention and control, corporate development "two hands"
Renfu Pharmaceutical Group is committed to high-quality development
Efforts to explore new ways of modern governance of mega-cities, and promoting high-quality development is a main thread running through it. Facing the general environment of the epidemic, Renfu Pharmaceutical Group focuses on its main business, and strives to accelerate high-quality development while doing a good job in epidemic prevention and control, so as to realize the healthy and orderly development of the group.
As the main reserve and distribution enterprise of emergency supplies for the prevention and control of the new crown pneumonia epidemic in Hubei Province, the two-level new crown pneumonia epidemic prevention and control headquarters material supply platform company of Hubei Province and Wuhan City, Renfu Pharmaceutical Group is fully committed to the prevention and control material reserve and distribution during the anti-epidemic period , Which strongly supported Hubei Province and Wuhan City’s emergency supplies for prevention and control.
In the critical period of recovery after the epidemic, the companies under the Renfu Pharmaceutical Group used pressure as the driving force to cultivate new opportunities in the crisis, and carried out various tasks around the three main lines of revitalizing the stock, laying out the future, and cultivating talents.
The mission must be reached, taking on the heavy responsibility of the prevention and control of material procurement, storage and distribution
After the Hubei Renfu Company, a subsidiary of Renfu Pharmaceutical Group, was ordered to join the Provincial Prevention and Control Headquarters Material Assurance Group on January 21, it immediately established a prevention and control leading group and an emergency command group, and formulated an emergency guarantee material supply plan, a personnel transportation plan, and an emergency The warehousing plan lays a solid foundation for the orderly warehousing of bulk emergency medical supplies in the later period.
On January 23, the Party Committee of Renfu Pharmaceutical Group established an anti-epidemic temporary party branch and formed a "vanguard of party members" to rush to the front line. Under the leadership of the party vanguard, employee volunteers from more than 30 group member companies formed a nearly 300-person anti-epidemic material procurement and distribution team, and the subsequent guarantee team increased to nearly 1,000.
Renfu Pharmaceutical Group gave full play to the company's distribution network advantages in Hubei Province, and played an important role in fighting the epidemic in Wuhan, Hubei Province, cities and prefectures, especially designated hospitals, Huoshenshan Hospital, Leishenshan Hospital, and various cabin hospitals. Strategic support role. During the epidemic, the company distributed more than 45 million pieces of protective materials and medical equipment such as masks, protective clothing, ventilators, including 6.1 million N95 masks, more than 24 million medical surgical masks, more than 14 million ordinary medical masks, and 680,000 protective clothing Multiple sets, more than 50 tons of sterilization products, more than 3,000 sets of various medical equipment such as ventilators, monitors, etc., serving more than 200 hospitals in Wuhan and Hubei Province at the second level and above, effectively ensuring the first-line material demand for anti-epidemic .
As of now, including international donations, the total value of donations from Renfu Pharmaceutical Group and its subsidiaries is nearly 40 million yuan, and the total value of donations from Renfu Pharmaceutical's joint controlling shareholder, Contemporary Group and partner companies is 70 million yuan overdue.
Revived after the epidemic, gather efforts to adhere to high-quality development
In the critical period of recovery after the epidemic, the companies under Renfu Pharmaceutical Group used pressure as the driving force to cultivate new opportunities in the crisis, and while resuming work and production, they insisted on high-quality development. While the enterprise develops in an orderly manner, it will promote the healthy development of upstream and downstream enterprises.
Yichang Renfu Pharmaceutical is currently the largest R&D and production base of narcotic drugs in Asia, and the only R&D and production enterprise in China that has a full range of fentanyl products. Recently, the Hubei Provincial Government issued the "Decision on Issuing the 8th Yangtze River Quality Award", and Yichang Renfu Pharmaceutical won the 8th Hubei Yangtze River Quality Award in 2019.
Recently, Yichang Renfu Pharmaceutical's Class 1 new drug remazolam besylate for injection obtained the drug registration certificate and was officially approved for marketing. This is also the first Class 1 new chemical drug approved in Hubei Province. The approval of this product marks a milestone in Yichang Renfu Pharmaceutical's R&D strength from following to leading.
Ren Foepke Pharmaceuticals is the first pharmaceutical preparation export company in Hubei Province that has passed the US FDA certification. It has a cGMP standard internationally first-class soft capsule preparation production workshop and quality inspection laboratory.